0001337013falseDecember 31Q12024P1Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesinfu:segmentxbrli:pureinfu:agreement00013370132024-01-012024-03-3100013370132024-05-0300013370132024-03-3100013370132023-12-3100013370132023-01-012023-03-310001337013us-gaap:CommonStockMember2022-12-310001337013us-gaap:AdditionalPaidInCapitalMember2022-12-310001337013us-gaap:RetainedEarningsMember2022-12-310001337013us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100013370132022-12-310001337013us-gaap:CommonStockMember2023-01-012023-03-310001337013us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001337013us-gaap:RetainedEarningsMember2023-01-012023-03-310001337013us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001337013us-gaap:CommonStockMember2023-03-310001337013us-gaap:AdditionalPaidInCapitalMember2023-03-310001337013us-gaap:RetainedEarningsMember2023-03-310001337013us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100013370132023-03-310001337013us-gaap:CommonStockMember2023-12-310001337013us-gaap:AdditionalPaidInCapitalMember2023-12-310001337013us-gaap:RetainedEarningsMember2023-12-310001337013us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001337013us-gaap:CommonStockMember2024-01-012024-03-310001337013us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001337013us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001337013us-gaap:RetainedEarningsMember2024-01-012024-03-310001337013us-gaap:CommonStockMember2024-03-310001337013us-gaap:AdditionalPaidInCapitalMember2024-03-310001337013us-gaap:RetainedEarningsMember2024-03-310001337013us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001337013us-gaap:TransferredAtPointInTimeMemberinfu:PatientServicesMemberus-gaap:ProductMember2024-01-012024-03-310001337013us-gaap:TransferredAtPointInTimeMemberinfu:PatientServicesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductMember2024-01-012024-03-310001337013us-gaap:TransferredAtPointInTimeMemberinfu:PatientServicesMemberus-gaap:ProductMember2023-01-012023-03-310001337013us-gaap:TransferredAtPointInTimeMemberinfu:PatientServicesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductMember2023-01-012023-03-310001337013us-gaap:TransferredAtPointInTimeMemberinfu:PatientServicesMemberinfu:ThirdPartyPayerRentalsMember2024-01-012024-03-310001337013us-gaap:TransferredAtPointInTimeMemberinfu:PatientServicesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberinfu:ThirdPartyPayerRentalsMember2024-01-012024-03-310001337013us-gaap:TransferredAtPointInTimeMemberinfu:PatientServicesMemberinfu:ThirdPartyPayerRentalsMember2023-01-012023-03-310001337013us-gaap:TransferredAtPointInTimeMemberinfu:PatientServicesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberinfu:ThirdPartyPayerRentalsMember2023-01-012023-03-310001337013infu:PatientServicesMemberinfu:DirectPayerRentalsMemberus-gaap:TransferredOverTimeMember2024-01-012024-03-310001337013infu:PatientServicesMemberinfu:DirectPayerRentalsMemberus-gaap:TransferredOverTimeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-03-310001337013infu:PatientServicesMemberinfu:DirectPayerRentalsMemberus-gaap:TransferredOverTimeMember2023-01-012023-03-310001337013infu:PatientServicesMemberinfu:DirectPayerRentalsMemberus-gaap:TransferredOverTimeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-03-310001337013infu:PatientServicesMemberus-gaap:TransferredOverTimeMemberinfu:ThirdPartyPayerRentalsMember2024-01-012024-03-310001337013infu:PatientServicesMemberus-gaap:TransferredOverTimeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberinfu:ThirdPartyPayerRentalsMember2024-01-012024-03-310001337013infu:PatientServicesMemberus-gaap:TransferredOverTimeMemberinfu:ThirdPartyPayerRentalsMember2023-01-012023-03-310001337013infu:PatientServicesMemberus-gaap:TransferredOverTimeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberinfu:ThirdPartyPayerRentalsMember2023-01-012023-03-310001337013infu:PatientServicesMember2024-01-012024-03-310001337013infu:PatientServicesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-03-310001337013infu:PatientServicesMember2023-01-012023-03-310001337013infu:PatientServicesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-03-310001337013us-gaap:TransferredAtPointInTimeMemberus-gaap:ProductMemberinfu:DeviceSolutionsMember2024-01-012024-03-310001337013us-gaap:TransferredAtPointInTimeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductMemberinfu:DeviceSolutionsMember2024-01-012024-03-310001337013us-gaap:TransferredAtPointInTimeMemberus-gaap:ProductMemberinfu:DeviceSolutionsMember2023-01-012023-03-310001337013us-gaap:TransferredAtPointInTimeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductMemberinfu:DeviceSolutionsMember2023-01-012023-03-310001337013us-gaap:TransferredAtPointInTimeMemberus-gaap:ServiceMemberinfu:DeviceSolutionsMember2024-01-012024-03-310001337013us-gaap:TransferredAtPointInTimeMemberus-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberinfu:DeviceSolutionsMember2024-01-012024-03-310001337013us-gaap:TransferredAtPointInTimeMemberus-gaap:ServiceMemberinfu:DeviceSolutionsMember2023-01-012023-03-310001337013us-gaap:TransferredAtPointInTimeMemberus-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberinfu:DeviceSolutionsMember2023-01-012023-03-310001337013us-gaap:ServiceMemberus-gaap:TransferredOverTimeMemberinfu:DeviceSolutionsMember2024-01-012024-03-310001337013us-gaap:ServiceMemberus-gaap:TransferredOverTimeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberinfu:DeviceSolutionsMember2024-01-012024-03-310001337013us-gaap:ServiceMemberus-gaap:TransferredOverTimeMemberinfu:DeviceSolutionsMember2023-01-012023-03-310001337013us-gaap:ServiceMemberus-gaap:TransferredOverTimeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberinfu:DeviceSolutionsMember2023-01-012023-03-310001337013us-gaap:TransferredOverTimeMemberinfu:DeviceSolutionsMember2024-01-012024-03-310001337013us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:TransferredOverTimeMemberinfu:DeviceSolutionsMember2024-01-012024-03-310001337013us-gaap:TransferredOverTimeMemberinfu:DeviceSolutionsMember2023-01-012023-03-310001337013us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:TransferredOverTimeMemberinfu:DeviceSolutionsMember2023-01-012023-03-310001337013infu:PatientServicesAndDeviceSolutionsMember2024-01-012024-03-310001337013infu:PatientServicesAndDeviceSolutionsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-03-310001337013infu:PatientServicesAndDeviceSolutionsMember2023-01-012023-03-310001337013infu:PatientServicesAndDeviceSolutionsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-03-310001337013infu:PatientServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001337013infu:PatientServicesMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001337013infu:DeviceSolutionsMember2024-01-012024-03-310001337013us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinfu:DeviceSolutionsMember2024-01-012024-03-310001337013infu:DeviceSolutionsMember2023-01-012023-03-310001337013us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinfu:DeviceSolutionsMember2023-01-012023-03-310001337013infu:PatientServicesAndDeviceSolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001337013infu:PatientServicesAndDeviceSolutionsMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001337013us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310001337013us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001337013srt:RestatementAdjustmentMember2024-03-310001337013srt:RestatementAdjustmentMemberus-gaap:OtherCurrentAssetsMember2024-03-310001337013us-gaap:OtherCurrentAssetsMember2024-01-012024-03-310001337013us-gaap:FurnitureAndFixturesMember2024-03-310001337013us-gaap:FurnitureAndFixturesMember2023-12-310001337013us-gaap:AutomobilesMember2024-03-310001337013us-gaap:AutomobilesMember2023-12-310001337013us-gaap:LeaseholdImprovementsMember2024-03-310001337013us-gaap:LeaseholdImprovementsMember2023-12-310001337013infu:DeviceSolutionsMember2023-12-310001337013infu:DeviceSolutionsMember2024-03-310001337013infu:PatientServicesMember2024-03-310001337013us-gaap:TradeNamesMember2024-03-310001337013us-gaap:TradeNamesMember2023-12-310001337013infu:PhysicianAndCustomerRelationshipsMember2024-03-310001337013infu:PhysicianAndCustomerRelationshipsMember2023-12-310001337013us-gaap:NoncompeteAgreementsMember2024-03-310001337013us-gaap:NoncompeteAgreementsMember2023-12-310001337013us-gaap:TechnologyBasedIntangibleAssetsMember2024-03-310001337013us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310001337013us-gaap:ComputerSoftwareIntangibleAssetMember2024-03-310001337013us-gaap:ComputerSoftwareIntangibleAssetMember2023-12-310001337013us-gaap:RevolvingCreditFacilityMemberinfu:The2021CreditAgreementMember2021-02-050001337013us-gaap:LetterOfCreditMemberinfu:The2021CreditAgreementMember2021-02-050001337013us-gaap:RevolvingCreditFacilityMemberinfu:The2021CreditAgreementMember2021-02-052021-02-050001337013infu:The2015CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-02-052021-02-050001337013infu:The2021CreditAgreementMember2021-02-052021-02-050001337013infu:The2021CreditAgreementMember2021-02-050001337013us-gaap:RevolvingCreditFacilityMemberinfu:The2021CreditAgreementMember2023-04-250001337013us-gaap:RevolvingCreditFacilityMemberinfu:The2021CreditAgreementMember2023-04-260001337013us-gaap:RevolvingCreditFacilityMember2024-03-310001337013us-gaap:RevolvingCreditFacilityMember2023-12-310001337013srt:MinimumMemberinfu:SecuredOvernightFinancingRateSOFRMemberinfu:TermBenchmarkLoansMemberinfu:The2021CreditAgreementMember2024-01-012024-03-310001337013infu:SecuredOvernightFinancingRateSOFRMemberinfu:TermBenchmarkLoansMemberinfu:The2021CreditAgreementMembersrt:MaximumMember2024-01-012024-03-310001337013srt:MinimumMemberinfu:The2021CreditAgreementMemberus-gaap:BaseRateMemberinfu:ABRLoansMember2024-01-012024-03-310001337013infu:The2021CreditAgreementMemberus-gaap:BaseRateMembersrt:MaximumMemberinfu:ABRLoansMember2024-01-012024-03-310001337013infu:TermBenchmarkLoansMemberinfu:The2021CreditAgreementMember2024-03-310001337013infu:SecuredOvernightFinancingRateSOFRMemberinfu:TermBenchmarkLoansMemberinfu:The2021CreditAgreementMember2024-01-012024-03-310001337013infu:The2021CreditAgreementMemberinfu:ABRLoansMember2024-03-310001337013srt:MinimumMemberinfu:The2021CreditAgreementMemberus-gaap:BaseRateMemberinfu:ABRLoansMember2024-03-310001337013infu:The2021CreditAgreementMemberus-gaap:BaseRateMemberinfu:ABRLoansMember2024-01-012024-03-310001337013us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-02-050001337013us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2021-02-052021-02-050001337013us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-05-110001337013us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-05-112023-05-110001337013us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2024-03-310001337013us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-12-310001337013us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310001337013us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001337013us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-03-310001337013us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-03-310001337013us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-310001337013us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-03-310001337013us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2024-01-012024-03-3100013370132021-06-300001337013us-gaap:RestrictedStockMember2023-12-310001337013us-gaap:RestrictedStockMember2024-01-012024-03-310001337013us-gaap:RestrictedStockMember2024-03-310001337013us-gaap:RestrictedStockMember2023-01-012023-03-310001337013infu:A2014EquityIncentivePlanMember2023-12-310001337013infu:A2014EquityIncentivePlanMember2023-01-012023-12-310001337013infu:A2014EquityIncentivePlanMember2024-01-012024-03-310001337013infu:A2014EquityIncentivePlanMember2024-03-310001337013infu:A2021EquityIncentivePlanMember2023-12-310001337013infu:A2021EquityIncentivePlanMember2023-01-012023-12-310001337013infu:A2021EquityIncentivePlanMember2024-01-012024-03-310001337013infu:A2021EquityIncentivePlanMember2024-03-310001337013us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001337013us-gaap:EmployeeStockOptionMember2024-03-310001337013srt:MinimumMemberinfu:OfficeLeasesWithRenewalOptionsNotReasonablyCertainToExerciseMember2024-03-310001337013infu:OfficeLeasesWithRenewalOptionsNotReasonablyCertainToExerciseMembersrt:MaximumMember2024-03-310001337013infu:SalesTypeLeaseNetInvestmentMember2024-03-310001337013infu:SalesTypeLeaseNetInvestmentMember2023-12-310001337013us-gaap:OperatingSegmentsMemberinfu:PatientServicesMember2024-01-012024-03-310001337013us-gaap:OperatingSegmentsMemberinfu:DeviceSolutionsMember2024-01-012024-03-310001337013infu:CorporateAndEliminationsMember2024-01-012024-03-310001337013us-gaap:OperatingSegmentsMemberinfu:PatientServicesMember2024-03-310001337013us-gaap:OperatingSegmentsMemberinfu:DeviceSolutionsMember2024-03-310001337013infu:CorporateAndEliminationsMember2024-03-310001337013us-gaap:OperatingSegmentsMemberinfu:PatientServicesMember2023-01-012023-03-310001337013us-gaap:OperatingSegmentsMemberinfu:DeviceSolutionsMember2023-01-012023-03-310001337013infu:CorporateAndEliminationsMember2023-01-012023-03-310001337013us-gaap:OperatingSegmentsMemberinfu:PatientServicesMember2023-03-310001337013us-gaap:OperatingSegmentsMemberinfu:DeviceSolutionsMember2023-03-310001337013infu:CorporateAndEliminationsMember2023-03-31

x    Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

¨     Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Registrant’s Telephone Number, including Area Code: (248) 291-1210

Securities Registered Pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of May 3, 2024, 21,295,254 shares of the registrant’s common stock, par value $0.0001 per share, were outstanding.

PART I—FINANCIAL INFORMATION

STOCKHOLDERS’ EQUITY

1.Basis of Presentation and Nature of Operations

The terms “InfuSystem”, the “Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem is a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care. The Company provides products and services to hospitals, oncology practices and facilities and other alternative site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. The Company operates in two reportable segments, Patient Services and Device Solutions. During the fiscal year ended December 31, 2023, the Company also operated through First Biomedical, Inc., a Kansas Corporation, which was a wholly-owned subsidiary that merged into InfuSystem, Inc. on January 1, 2024.

The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying unaudited condensed consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on April 10, 2024.

The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

2.Recent Accounting Pronouncements and Developments

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (ASC 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 expands the disclosure requirements for reportable segments by requiring enhanced disclosures about significant segment expenses. Under the new standard, entities must disclose an amount for other segment items by reportable segment and a description of its composition. The other segment items category is the difference between segment revenue less the significant expenses disclosed and each reported measure of segment profit or loss. Additionally, entities must disclose at least one measure of assessing segment performance and the title and position of the chief operating decision-maker ("CODM") and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance. The amendments are effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments are to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of ASU 2023-07 on its consolidated financial statements and related disclosures.

In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures. ASU 2023-09 enhances existing income tax disclosures primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments in this ASU requires public entities to disclose a tabular tax rate reconciliation, using both percentages and currency, with specific categories. Public entities are also required to provide a qualitative description of the states and local jurisdictions that make up the majority of the effect of the state and local income tax category and the net amount of income taxes paid, disaggregated by federal, state and foreign taxes and also disaggregated by individual jurisdictions. The amendments also remove certain disclosures that are no longer considered cost beneficial. The amendments are effective prospectively for annual periods beginning after December 15, 2024, and early adoption and retrospective application are permitted. The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statements and related disclosures.

In March 2024, the SEC issued final rules on climate-related disclosures that will require annual disclosure of material climate-related risks and material direct greenhouse gas emissions from operations owned or controlled (Scope 1) and material indirect greenhouse gas emissions from purchased energy consumed in owned or controlled operations (Scope 2).

Additionally, the rules require disclosure in the notes to the financial statements of the effects of severe weather events and other natural conditions, subject to certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates. These rules also require disclosure of climate risk oversight practices of the Board of Directors and management, and the disclosure of governance, risk management and strategy related to material climate-related risks. In April 2024, the SEC voluntarily stayed the new rules pending the completion of judicial review. The disclosure requirements, if ultimately upheld as adopted, will begin phasing in for reports and registration statements including financial information with respect to annual periods beginning in our fiscal 2027. We are currently evaluating the impact of adoption of these final rules on our disclosures.

3.Revenue

The following table presents the Company’s disaggregated revenue by offering type (in thousands):

The change in contract assets during the three months ended March 31, 2024 was mainly due to $2.9 million of revenue recognized for which the payment is subject to conditions other than the passage of time, partially offset by $2.8 million of contract assets reclassified to accounts receivable as our right to consideration for these contract assets became unconditional. Contract assets are included in other current assets on the Company's Condensed Consolidated Balance Sheets.

4.Medical Equipment

Medical equipment consisted of the following (in thousands):

Depreciation expense for medical equipment for the three months ended March 31, 2024 was $2.3 million compared to $2.7 million for the same prior year period, respectively. This expense was recorded in “cost of revenues” for each period. The pump reserve for medical equipment in rental service represents an estimate for medical equipment that is considered to be missing. The reserve calculated is equal to the net book value of assets that have not returned from the field within a certain timeframe. For the three months ended March 31, 2024 and 2023, $2.7 million and $1.1 million of current liabilities related to non-cash purchases of medical equipment and property, respectively, had not been included in investing activities in the Condensed Consolidated Statements of Cash Flows. These amounts will be included as a cash outflow from investing activities when paid.

5.Property and Equipment

Property and equipment consisted of the following (in thousands):

Depreciation expense for property and equipment for both the three months ended March 31, 2024 and 2023 was $0.3 million. This expense was recorded in “general and administrative expenses” for each period.

6.Goodwill & Intangible Assets

The changes in the carrying value of goodwill by segment for the three months ended March 31, 2024 are as follows (in thousands):

						Device Solutions (a)
Balance as of December 31, 2023						$	3,710
Goodwill acquired						—
Balance as of March 31, 2024						$	3,710
(a) The Patient Services segment had no recorded goodwill during the reported periods.

The carrying amount and accumulated amortization of intangible assets consisted of the following (in thousands):

Amortization expense for both the three months ended March 31, 2024 and 2023 was $0.2 million. This expense was recorded in “amortization of intangibles expenses” for each period. Expected remaining annual amortization expense for the next five years for intangible assets recorded as of March 31, 2024 is as follows (in thousands):

7.Debt

On February 5, 2021, the Company entered into a Credit Agreement (the “2021 Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), sole bookrunner and sole lead arranger, and the lenders party thereto.

The borrowers under the 2021 Credit Agreement are InfuSystem Holdings, Inc. and its subsidiaries (collectively, the “Borrowers”).

The 2021 Credit Agreement provides for a revolving credit facility (the “Revolving Facility”) of $75.0 million, that matures on February 5, 2026. The Revolving Facility may be increased by $25.0 million, subject to certain conditions, including the consent of the Agent and obtaining necessary commitments. The lenders under the 2021 Credit Agreement may issue up to $7.0 million in letters of credit subject to the satisfaction of certain conditions. On February 5, 2021, the Borrowers made an initial borrowing of $30.0 million under the Revolving Facility. Proceeds from the loan, along with approximately $8.2 million in cash, were used to repay all amounts due under the Company’s then existing credit facility dated March 23, 2015 (the “2015 Credit Agreement”).

The 2021 Credit Agreement has customary representations and warranties. The ability to borrow under the facility is subject to ongoing compliance with a number of customary affirmative and negative covenants, including limitations on indebtedness, liens, mergers, acquisitions, investments, asset sales, affiliate transactions and restricted payments, as well as financial covenants, including the following:

•a minimum fixed charge coverage ratio (defined as the ratio of consolidated EBITDA (as defined in the 2021 Credit Agreement) less 50% of depreciation expense), to consolidated fixed charges (as defined in the 2021 Credit Agreement)) for the prior four most recently ended calendar quarters of 1.20 to 1.00; and

•a maximum leverage ratio (defined as total indebtedness to EBITDA for the prior four most recently ended calendar quarters) of 3.50 to 1.00.

The 2021 Credit Agreement includes customary events of default. The occurrence of an event of default will permit the lenders to terminate commitments to lend under the Revolving Facility and accelerate payment of all amounts outstanding thereunder.

Simultaneous with the execution of the 2021 Credit Agreement, the Company entered into a Pledge and Security Agreement to secure repayment of the obligations of the Borrowers. Under the Pledge and Security Agreement, each Borrower has granted to the Agent, for the benefit of various secured parties, a first priority security interest in substantially all of the personal property assets of each of the Borrowers, including the shares of each of Holdings, ISI and First Biomedical and the equity interests of IFC.

On April 26, 2023, the Company entered into a First Amendment to the 2021 Credit Agreement (the “First Amendment”) with the Agent and the lenders party thereto, which amended the 2021 Credit Agreement, to provide for, among other things: (i) an extension of the maturity date for the 2021 Credit Agreement to April 26, 2028, (ii) the replacement of London Interbank Offered Rate (“LIBOR”) with Adjusted Term Secured Overnight Financing Rate (“SOFR”) as a benchmark interest rate, and (iii) an increase of the maximum dollar amount of incremental revolving loans from $25 million to $35 million. Incremental revolving loans continue to be subject to certain conditions, including the consent of the Agent and obtaining necessary commitments.

The 2021 Credit Agreement and First Amendment were accounted for as debt modifications. As of March 31, 2024, the Company was in compliance with all debt-related covenants under the 2021 Credit Agreement, as amended.

The following table illustrates the net availability under the Revolving Facility as of the applicable balance sheet date (in thousands):

The Company had future maturities of its long-term debt as of March 31, 2024 as follows (in thousands):

The following is a breakdown of the Company’s current and long-term debt (in thousands):

As of March 31, 2024, amounts outstanding under the Revolving Facility provided under the 2021 Credit Agreement, as amended, bear interest at a variable rate equal to, at the Company’s election, Adjusted Term SOFR for Term Benchmark loans or an Alternative Base Rate for ABR loans, as defined by the First Amendment, plus a spread that will vary depending upon the Company’s leverage ratio. The spread ranges from 2.00% to 3.00% for Term Benchmark Loans and 1.00% to 2.00% for base rate loans. The weighted-average Term Benchmark loan rate at March 31, 2024 was 7.42% (Adjusted Term SOFR of 5.42% plus 2.00%). The actual ABR loan rate at March 31, 2024 was 9.50% (lender’s prime rate of 8.50% plus 1.00%).

8.Derivative Financial Instruments and Hedging Activities

In February 2021, the Company adopted a derivative investment policy, which provides guidelines and objectives related to managing financial and operational exposures arising from market changes in short term interest rates. In accordance with this policy, the Company can enter into interest rate swaps or similar instruments, will endeavor to evaluate all the risks inherent in a transaction before entering into a derivative financial instrument and will not enter into derivative financial instruments for speculative or trading purposes. Hedging relationships are formally documented at the inception of the hedge and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment.

The Company is exposed to interest rate risk related to its variable rate debt obligations under the 2021 Credit Agreement. In order to manage the volatility in interest rate markets, in February 2021, the Company entered into two interest rate swap agreements to manage exposure arising from this risk. On a combined basis, the agreements had a constant notional amount over a five-year term that would have ended on February 5, 2026. While they were outstanding, each agreement paid the Company 30-day LIBOR on the notional amount and the Company paid a fixed rate of interest equal to 0.73%. These derivative instruments were considered cash flow hedges. On May 11, 2023, these two swaps were settled and a new swap was entered into with different terms that aligned with changes in the 2021 Credit Agreement arising from the First Amendment. The new swap has a constant notional amount over a five-year term that ends on April 26, 2028. The agreement pays the Company 30-day SOFR on the notional amount and the Company pays a fixed rate of interest equal to 1.74%. The Company does not have any other derivative financial instruments.

The fair values of the Company’s derivative financial instruments are categorized as Level II of the fair value hierarchy as the values are derived using the market approach based on observable market inputs including quoted prices of similar instruments and interest rate forward curves.

The tables below present the location and gross fair value amounts of the Company's derivative financial instruments and the associated notional amounts designated as cash flow hedges as of the applicable balance sheet date (in thousands):

The table below presents the effect of our derivative financial instruments designated as hedging instruments in accumulated other comprehensive income (“AOCI”) (in thousands):

The Company did not incur any hedge ineffectiveness during the three months ended March 31, 2024.

9.Income Taxes

During the three months ended March 31, 2024, the Company recorded a benefit from income taxes totaling $0.2 million on pre-tax losses of $1.3 million, representing an effective tax rate of 14.3%. During the three months ended March 31, 2023, the Company recorded a benefit from income taxes totaling $0.3 million on pre-tax losses of $0.6 million, representing an effective tax rate of 48.2%. These rates differed from the U.S. statutory rate mainly due to the effects of local, state and foreign jurisdiction income taxes, limitations on the deductions of certain expenses including meals and entertainment expense and management compensation and differences between expense recognized for book purposes versus tax purposes associated with equity compensation expense. The impact of permanent differences weighs heavier on the effective tax rate when pre-tax earnings are close to break even.

10.Commitments, Contingencies and Litigation

From time to time in the ordinary course of its business, the Company may be involved in legal and regulatory proceedings, the outcomes of which may not be determinable. The results of litigation and regulatory proceedings are inherently unpredictable. Any claims against the Company, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. The Company is not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages and, until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. The Company has insurance policies covering potential losses where such coverage is cost effective.

The Company is not at this time involved in any proceedings that the Company currently believes could have a material effect on the Company’s financial condition, results of operations or cash flows.

11.Loss Per Share

Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted loss per share computations:

For the three months ended March 31, 2024 and 2023, all outstanding options and unvested restricted stock units were anti-dilutive due to the Company's net losses for the periods and therefore not included in the calculations.

On June 30, 2021, our Board of Directors approved a stock repurchase program (the “Share Repurchase Program”) that authorizes the Company to repurchase up to $20.0 million of the Company’s outstanding common stock through June 30, 2024. Repurchases under the Share Repurchase Program are subject to market conditions, the periodic capital needs of the Company’s operating activities, and the continued satisfaction of all covenants under the Company’s existing 2021 Credit Agreement, as amended. Repurchases under the Share Repurchase Program may take place in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan. The Share Repurchase Program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time at the discretion of the Board. As of March 31, 2024, the Company had repurchased and retired approximately $6.2 million, or 553,149 shares, of the Company's outstanding common stock under the Share Repurchase Program.

12.Share-Based Compensation

The following tables summarize the activity during the period under the Company's 2014 Amended and Restated Stock Incentive Plan (the "2014 Plan") and 2021 Equity Incentive Plan (the "2021 Plan").

For the three months ended March 31, 2024, there were no grants, vesting, or forfeitures of PSUs.

(a) Aggregate Intrinsic Value - no exercisable options were in-the-money as of March 31, 2024

The following is the average fair value per share estimated on the date of grant and the assumptions used for options granted:

For the three months ended March 31, 2023, the Company did not grant any options, and thus that time period is excluded from the table above.

13.Leases

The Company’s operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next seven years. The Company’s leases do not contain any restrictive covenants. The Company’s office leases generally contain renewal options for periods ranging from one to five years. Because the Company is not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. The Company’s office leases do not contain any material residual value guarantees. The Company’s equipment leases generally do not contain renewal options.

Payments due under the Company’s operating leases include fixed payments as well as variable payments. For the Company’s office leases, variable payments include amounts for the Company’s proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company’s equipment leases, variable payments may consist of sales taxes, property taxes and other fees.

The components of lease costs for the three months ended March 31, 2024 and 2023 are as follows (in thousands):

Supplemental cash flow information and non-cash activity related to the Company’s leases are as follows (in thousands):

Weighted average remaining lease terms and discount rates for the Company’s operating leases are as follows:

Future maturities of lease liabilities as of March 31, 2024 are as follows (in thousands):

The long-term portion of the lease liabilities included in the amounts above is $5.3 million with the remainder included in other current liabilities in the Condensed Consolidated Balance Sheet.

We lease medical equipment to customers, often in conjunction with arrangements to provide consumable medical products. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options, varies by customer. The Company elected the “combining lease and non-lease components” practical expedient for all qualifying non-lease components.

The components of the Company’s lease revenues consisted of the following (in thousands):

			Three Months Ended March 31,
			2024						2023
Net operating lease revenue			$	6,111					$	5,910
Sales-type lease revenue			257						494
Total lease revenue			$	6,368					$	6,404

The components of our net investment in sales-type leases as of March 31, 2024 and December 31, 2023 were (in thousands):

Our net investment in sales-type leases is classified as follows in the accompanying condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023 were (in thousands):

Future maturities of sales-type leases as of March 31, 2024 are as follows (in thousands):

14.Business Segment Information

The Company’s reportable segments are organized based on service platforms, with the Patient Services segment reflecting higher margin rental revenues that generally include payments made by third-party and direct payers and the Device Solutions segment reflecting lower margin product sales, direct payer rental and service revenues. Resources are allocated and performance is assessed for these segments by the Company’s Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker. The Company believes that reporting performance at the gross profit level is the best indicator of segment performance.

The financial information summarized below is presented by reportable segment for the three months ended March 31, 2024 and 2023:

The terms “InfuSystem”, the “Company”, “we”, “our” and “us” used herein refer to InfuSystem Holdings, Inc. and its subsidiaries.

Certain statements contained in this quarterly report on Form 10-Q are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, the effect of the coronavirus (“COVID-19”) pandemic or any resurgence thereof on our business, potential changes in healthcare payer mix and overall healthcare reimbursement, including the Centers for Medicare and Medicaid Services (“CMS”) competitive bidding and fee schedule reductions, sequestration, concentration of customers, increased focus on early detection of cancer, competitive treatments, dependency on Medicare Supplier Number, availability of chemotherapy drugs, global financial conditions and recessionary risks, rising inflation and interest rates, labor and supply chain disruptions, changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers, risks in acquisitions & joint ventures, U.S. Healthcare Reform, relationships with healthcare professionals and organizations, technological changes related to infusion therapy, the Company’s ability to implement information technology improvements and to respond to technological changes, the ability of the Company to successfully integrate acquired businesses, dependency on key personnel, systemic pressures in the banking sector, including disruptions to credit markets, dependency on banking relations and the ability to comply with our credit facility covenants, the Company's ability to remediate its previously disclosed material weaknesses in internal control over financial reporting, and other risks associated with our common stock, as well as any litigation in which the Company may be involved from time to time; and other risk factors as discussed in the Company’s annual report on Form 10-K for the year ended December 31, 2023 filed on April 10, 2024, this quarterly report on Form 10-Q and in other filings made by the Company from time to time with the Securities and Exchange Commission (“SEC”). Our annual report on Form 10-K is available on the SEC’s EDGAR website at www.sec.gov, and a copy may also be obtained by contacting the Company. All forward-looking statements made in this Form 10-Q speak only as of the date of this report. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements, except as required by law.

We are a leading national health care service provider, facilitating outpatient care for Durable Medical Equipment manufacturers and health care providers. We provide our products and services to hospitals, oncology practices, ambulatory surgery centers, and other alternate site health care providers. Our headquarters is in Rochester Hills, Michigan, and we operate our business from a total of seven locations in the United States and Canada. We deliver local, field-based customer support, and we operate pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. InfuSystem, Inc., a wholly-owned subsidiary of the Company, is accredited by the Community Health Accreditation Partner (CHAP). We are also ISO 9001 certified at our Kansas, Michigan, Massachusetts, Canada and Santa Fe Springs, California locations and ISO 13485 certified at our Bakersfield, California location. During the fiscal year ended December 31, 2023, the Company also operated through First Biomedical, Inc., a Kansas Corporation, which was a wholly-owned subsidiary that merged into InfuSystem, Inc. on January 1, 2024.

InfuSystem competes for and retains its business primarily on the basis of its long participation and strong reputation in the Durable Medical Equipment space, its long-standing relationships with Durable Medical Equipment manufacturers and its health care provider customers, and the high levels of service it provides. Current barriers to entry for potential competitors are created by our: (i) growing number of third-party payer networks under contract; (ii) economies of scale, which allow for predictable reimbursement and less costly purchase and management of the pumps, respectively; (iii) established, long-standing relationships as a provider of pumps to outpatient oncology practices in the U.S.

and Canada; (iv) pump fleet of ambulatory and large volume infusion pumps for rent and for sale, which may allow us to be more responsive to the needs of physicians, outpatient oncology practices, hospitals, outpatient surgery centers, homecare practices, patient rehabilitation centers and patients than a new market entrant; (v) seven geographic locations in the U.S. and Canada that allow for same day or next day delivery of pumps; and (vi) pump repair and service capabilities at all of these facilities and at our customer's locations. We do not perform any research and development on pumps, but we have made, and continue to make, investments in our information technology applications.

Our Patient Services segment’s core purpose is to seek opportunities to grow our business by leveraging our unique know-how in clinic-to-home health care involving Durable Medical Equipment, our logistics and billing capabilities, our growing network of third-party payers under contract, and our clinical and biomedical capabilities. This leverage may take the form of new products and/or services, strategic alliances, joint ventures and/or acquisitions. The leading service within our Patient Services segment is to supply electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states (“Oncology Business”). Colorectal cancer is the fourth most prevalent form of cancer in the United States, according to the American Cancer Society, and the standard of care for the treatment of colorectal cancer relies upon continuous chemotherapy infusions delivered via ambulatory infusion pumps. One of the goals for the Patient Services segment is to expand into treatment of other types of cancers. There are a number of approved treatment protocols for pancreatic, head and neck, esophageal and other types of cancers, as well as other disease states that present opportunities for growth. There are also a number of other drugs currently approved by the U.S. Food and Drug Administration (the “FDA”), as well as agents in the pharmaceutical development pipeline, which we believe could potentially be used with continuous infusion protocols for the treatment of diseases other than colorectal cancer. Additional drugs or protocols currently in clinical trials may also obtain regulatory approval over the next several years. If these new drugs or protocols obtain regulatory approval for use with continuous infusion protocols, we expect the pharmaceutical companies to focus their sales and marketing efforts on promoting the new drugs and protocols to physicians, which could benefit us.

Furthermore, our Oncology Business focuses mainly on the continuous infusion of chemotherapy. Continuous infusion of chemotherapy can be described as the gradual administration of a drug via a small, lightweight, portable infusion pump over a prolonged period of time. A cancer patient can receive his or her medicine anywhere from one to 30 days per month depending on the chemotherapy regimen that is most appropriate to that individual’s health status and disease state. This may be followed by periods of rest and then repeated cycles with treatment goals of progression-free disease survival. This drug administration method has replaced intravenous push or bolus administration in specific circumstances. The advantages of slow continuous low doses of certain drugs are well documented. Clinical studies support the use of continuous infusion chemotherapy for decreased toxicity without loss of anti-tumor efficacy. The 2015 National Comprehensive Cancer Network (“NCCN”) Guidelines recommend the use of continuous infusion for treatment of numerous cancer diagnoses. We believe that the growth of continuous infusion therapy is driven by three factors: (i) evidence of improved clinical outcomes; (ii) lower toxicity and side effects; and (iii) a favorable reimbursement environment.

We believe that oncology practitioners have a heightened sensitivity to providing quality service and to their ability to obtain reimbursement for services they provide. Simultaneously, the Center for Medicare and Medicaid Services and private insurers are increasingly focused on evidence-based medicine to inform their reimbursement decisions — that is, aligning reimbursement with clinical outcomes and adherence to standards of care. Continuous infusion therapy is a main component of the standard of care for certain types of cancers because clinical evidence demonstrates superior outcomes. Payers’ recognition of this benefit is reflected in their relative reimbursement policies for clinical services related to the delivery of this care.

Additional areas of focus for our Patient Services segment are as follows:

•Pain Management – providing our ambulatory pumps, products, and services for pain management in the area of post-surgical continuous peripheral nerve block.

•Wound Care – launched in November 2022, the Company established a partnership, SI Wound Care, LLC (“SI Wound Care”), with Sanara MedTech Inc. “Sanara”). The partnership will focus on delivering a complete wound care solution targeted at improving patient outcomes, lowering the cost of care, and increasing patient and provider satisfaction. The partnership is expected to enable InfuSystem to offer innovative products including negative pressure wound therapy (“NPWT”) devices and supplies from Cork Medical LLC's (“Cork”) and Genadyne Biotechnologies Inc. and Sanara's advanced wound care product line to new customers through the jointly controlled entity.

•Acquisitions – we believe there are opportunities to acquire smaller, regional health care service providers, in whole or part that perform similar services to us but do not have the national market access, network of third-party payer contracts or operating economies of scale that we currently enjoy. We may also pursue acquisition opportunities of companies that perform similar services, but offer different therapies or utilize different devices.

•Information technology-based services - we also plan to continue to capitalize on key new information technology-based services such as EXPRESS, InfuBus or InfuConnect, Pump Portal, DeviceHub and BlockPain Dashboard®.

The payer environment within our Patient Services segment is in a constant state of change. We continue to extend our considerable breadth of payer networks under contract as patients move into different insurance coverage plans, including Medicaid and Insurance Marketplace products. In some cases, this may slightly reduce our aggregate billed revenues payment rate but result in an overall increase in collected revenues, due to a reduction in concessions. Consequently, we are increasingly focused on revenues net of concessions.

Our Device Solutions segment’s core service is to: (i) sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment; (ii) sell treatment-related consumables; and (iii) provide biomedical maintenance services on medical equipment that include recertification, annual preventative maintenance and repair services for oncology practices as well as other alternate site settings, including, home care and home infusion providers, skilled nursing facilities, pain centers and others. We provide biomedical services at both our facilities and at our customers' locations. We also provide these products and services to customers in the hospital market. We purchase new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. We repair, refurbish and provide biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within our ambulatory infusion pump management service.

The following represents the Company’s results of operations for the three months ended March 31, 2024 and 2023:

Net revenues for the three-month period ended March 31, 2024 (“three-month period of 2024”) were $32.0 million, an increase of $1.6 million, or 5.4%, compared to $30.4 million for the three-month period ended March 31, 2023 (“three-month period of 2023”). The increase included higher net revenues for the Device Solutions segment offset partially by lower revenue for the Patient Services segment.

Patient Services net revenue of $18.6 million decreased $0.2 million, or 1.0%, during the three-month period of 2024 compared to the same prior year period. This decrease was primarily attributable to decreased third-party payer collections on billings totaling approximately $0.5 million and lower revenue from sales-type leases of NPWT pumps, which decreased by $0.3 million, both of which had tough comparisons to strong prior year amounts. These decreases were partially offset by higher treatment volume in both Oncology and Wound Care.

Device Solutions net revenue of $13.4 million increased $1.8 million, or 15.6%, during the three-month period of 2024 compared to the same prior year period. This increase included higher biomedical services revenue, which increased by $1.0 million, or 31%, higher sales of medical equipment, which increased by $0.6 million, or 40% and higher rental equipment revenue, which increased by $0.3 million, compared to the same prior year period. These increases were partially offset by lower sales of disposable medical supplies which decreased by $0.1 million. The increased biomedical revenue was mainly attributable to increased revenue from the master services agreement that we entered into in April 2022.

Gross profit of $16.5 million for the three-month period of 2024 increased $1.5 million, or 10.2%, from $15.0 million for the three-month period of 2023. This increase was due to the increase in net revenues and by a higher gross margin. Gross margin increased to 51.5% during the three-month period of 2024 compared to 49.2% during the same prior year period. This increase was due to increases in gross margin for both the Patient Services and Device Solutions segments.

Patient Services gross profit was $12.3 million during the three-month period of 2024, representing an increase of $0.7 million, or 6.4%, compared to the same prior year period. The improvement reflected a higher gross margin, which increased from the prior year by 4.5% to 66.0%. The higher gross margin was the result of a change in product mix favoring higher margin revenues. These improvements were partially offset by lower third-party payer collections on billings. The favorable gross margin mix was mainly related to the decrease in revenue related to NPWT equipment leases, which have a lower average gross margin than other Patient Services revenue categories.

Device Solutions gross profit during the three-month period of 2024 was $4.2 million, representing a increase of $0.8 million, or 23.2%, compared to the same prior year period. This increase was due to the higher net revenue and due to an increase in gross margin. The Device Solutions gross margin was 31.3% during the current period, which was 1.9% higher than the same prior year period. This increase was due to an improvement in the absorption of direct expenses for the master services agreement launched during 2022 and accelerated during the first quarter of 2023. During the first quarter of 2023, the Company experienced an increase in labor costs related to an increase in the number of biomedical technicians and other expenses associated with the rapid on-boarding of the master services agreement. Some of the additional labor costs included training activities and other labor expenses associated with building a larger team in order to have the capacity required to support much higher planned revenue volume. Over time, higher revenue levels have begun to absorb a portion of these increased labor costs resulting in the improved gross margin. We estimate that further gross margin improvements will be gained as cost reduction and productivity improvement activities continue to be developed and deployed.

Selling and marketing expenses for the three-month period of 2024 were $3.4 million, representing an increase of $0.2 million, or 4.7%, compared to selling and marketing expenses for the three-month period of 2023. Selling and marketing expenses consist of sales personnel salaries, commissions and associated fringe benefit and payroll-related items, marketing, travel and entertainment and other miscellaneous expenses. Selling and marketing expenses as a percentage of net revenues was 10.6% for both the current and prior year periods.

G&A expenses for the three-month period of 2024 were $13.7 million, an increase of $2.1 million, or 18.2%, from the three-month period of 2023. G&A expenses during these periods consisted primarily of accounting, administrative, third-party payer billing and contract services, customer service, nurses on staff, new product services, service center personnel salaries, fringe benefits and other payroll-related items, professional fees, legal fees, stock-based compensation, insurance and other miscellaneous items. Additionally, the amount for 2024 included a one-time $0.6 million payment to a former member of the board of directors related to a Cooperation Agreement and a one-time payment to the Company's former audit firm for services related to their consent to include their prior year audit report in our 2023 annual report totaling $0.3 million. The remaining increase of $1.2 million included timing-related higher management incentive compensation and stock-based compensation expenses of $0.4 million and $0.3 million, respectively, and other increased expenses totaling $0.5 million. The other increases were associated with revenue volume growth including the cost of additional personnel, information technology and general business expenses and included inflationary increases. G&A expenses as a percentage of net revenues for the three-month period of 2024 increased to 42.8% compared to 38.1% for the same prior year period.

During the three-month period of 2024, other income and expense included interest expense of $0.5 million, which was slightly lower than interest expense for the three-month period of 2023. This decrease was due to a decrease in outstanding borrowings on the 2021 Credit Agreement, as amended, (defined below) revolving line of credit partially offset by higher average interest rates.

During the three-month period of 2024, the Company recorded a benefit from income taxes totaling $0.2 million on pre-tax losses of $1.3 million, representing an effective tax rate of 14.3%. During the three-month period of 2023, the Company recorded a benefit from income taxes totaling $0.3 million on pre-tax losses of $0.6 million, representing an effective tax rate of 48.2%. These rates differed from the U.S. statutory rate mainly due to the effects of local, state and foreign jurisdiction income taxes, limitations on the deductions of certain expenses including meals and entertainment expense and management compensation and differences between expense recognized for book purposes versus tax purposes associated with equity compensation expense. The impact of permanent differences weighs heavier on the effective tax rate when pre-tax earnings are close to break even.

Overview:

We finance our operations and capital expenditures with cash generated from operations and borrowings under our existing credit agreement. On February 5, 2021, we and certain of our subsidiaries, as borrowers, entered into a Credit Agreement (the “2021 Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, sole bookrunner and sole lead arranger (the “Agent”), and the lenders party thereto, which replaced our then existing credit facility. On April 26, 2023, the Company entered into a First Amendment to the 2021 Credit Agreement (the “First Amendment”) with the Agent and the lenders party thereto, which amended the 2021 Credit Agreement. See Note 7 (Debt) in the notes to the accompanying unaudited condensed consolidated financial statements for additional information regarding the 2021 Credit Agreement and the First Amendment.

The following table summarizes our available liquidity (in thousands):

Our liquidity and borrowing plans are established to align with our financial and strategic planning processes and ensure we have the necessary funding to meet our operating commitments, which primarily include the purchase of medical equipment, inventory, payroll and general expenses. We also take into consideration our overall capital allocation strategy, which includes investment for future organic growth, potential acquisitions and share repurchases.

We believe we have adequate sources of liquidity and funding available to meet our liquidity requirements for at least the next year from the filing date of this report, as well as for our currently anticipated long-term needs, including our long-term lease obligations discussed above in Note 13 (Leases) in the notes to the accompanying unaudited condensed consolidated financial statements. However, any projections of future earnings and cash flows are subject to substantial uncertainty, including factors such as the successful execution of our business plan and general economic conditions. We may need to access debt and equity markets in the future if unforeseen costs or opportunities arise, to meet working capital requirements, fund acquisitions or investments or repay indebtedness under the 2021 Credit Agreement, as amended. If we need to obtain new debt or equity financing in the future, the terms and availability of such financing may be impacted by economic and financial market conditions as well as our financial condition and results of operations at the time we seek additional financing.

The following table illustrates the net availability under the revolving credit facility (“Revolving Facility”) under the 2021 Credit Agreement, as amended, as of the applicable balance sheet date (in thousands):

As of March 31, 2024, amounts outstanding under the Revolving Facility provided under the 2021 Credit Agreement, as amended, bear interest at a variable rate equal to, at the Company’s election, Adjusted Term SOFR for Term Benchmark loans or an Alternative Base Rate for ABR loans, as defined by the First Amendment, plus a spread that will vary depending upon the Company’s leverage ratio. The spread ranges from 2.00% to 3.00% for Term Benchmark Loans and 1.00% to 2.00% for base rate loans. The weighted-average Term Benchmark loan rate at March 31, 2024 was 7.42% (Adjusted Term SOFR of 5.42% plus 2.00%). The actual ABR loan rate at March 31, 2024 was 9.50% (lender’s prime rate of 8.50% plus 1.00%). As of March 31, 2024, the Company was in compliance with all debt-related covenants under the 2021 Credit Agreement, as amended.

On June 30, 2021, our Board of Directors approved a stock repurchase program (the “Share Repurchase Program”) that authorizes the Company to repurchase up to $20.0 million of the Company’s outstanding common stock through June 30, 2024. Repurchases under the Share Repurchase Program are subject to market conditions, the periodic capital needs of the Company’s operating activities, and the continued satisfaction of all covenants under the Company’s existing 2021 Credit Agreement, as amended. Repurchases under the Share Repurchase Program may take place in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan. The Share Repurchase Program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time at the discretion of the Board.

As of March 31, 2024, the Company had repurchased and retired approximately $6.2 million, or 553,149 shares, of the Company's outstanding common stock under the Share Repurchase Program.

The following table summarizes our cash flows (in thousands):

Operating Cash Flow. Operating cash flows provided $0.4 million in cash during the three-month period of 2024 and used $0.2 million of cash during the three-month period of 2023. This $0.5 million favorable difference was attributable to a reduction of cash used to fund working capital items, which was $1.5 million during three-month period of 2024 compared to $3.1 million during three-month period of 2023, a decrease of $1.6 million. This amount was offset by a decrease in net loss adjusted for non-cash items, which was $1.9 million during the three-month period of 2024 compared to $3.0 million during the three-month period of 2023, a decrease of $1.1 million. The decrease in net loss adjusted for non-cash items was primarily attributable to the increased general and administrative expenses, offset partially by the higher revenue and gross profit described above. The use of cash for working capital items during the three-month period of 2024 included a $1.1 million decrease in accounts payable and other liabilities net of capital items, a $0.7 million increase in other current assets and a $0.2 million increase in accounts receivable. These cash flow uses were partially offset by a $0.2 million decrease in inventories and a $0.4 million decrease in other assets. The cash used for working capital items during the three-month period of 2023 included a $1.0 million increase in accounts receivable, a $0.8 million increase in inventories, a $0.8 million increase in other current assets and a $0.8 million increase in other assets. These were partially offset by a $0.3 million increase in accounts payable and other liabilities net of capital items.

The increase in accounts receivable during both periods was mainly due to the increase in revenue during for each period. This increase was greater during the three-month period of 2023 when the revenue was growing at a higher rate and increased revenue attributable to sales-type leases was included, which resulted in higher lease receivables (of which the long-term portion is included in other assets versus accounts receivable) and to the biomedical master services agreement described above, a part of which increased the related contract asset (which is included in other current assets versus accounts receivable). Revenue increased in the three-month period of 2024, but at a lower rate than the three-month period of 2023, largely resulting in an increased accounts receivable balance. Accounts payable and other liabilities net of capital items decreased by $1.1 million during the three-month period of 2024 and increased $0.3 million during the three-month period of 2023, representing a $1.4 million unfavorable cash flow swing, mainly due to an increase in the amount paid in 2024 for the 2023 short-term incentive bonus plan as compared to the amount paid in 2023 for the 2022 short-term incentive bonus plan. The increase in inventories during 2023 reflected the higher revenue growth during that period. The decrease in other assets was due to lower long-term lease receivables due to customer payments received and a decrease in the amount of equipment sales on leases during 2024 as compared to 2023.

Investing Cash Flow. Net cash used in investing activities was $0.4 million for the three-month period of 2024 compared to $3.1 million for the three-month period of 2023, a decrease of $2.6 million. The decrease was due to a decrease totaling $2.6 million in cash used to purchase medical equipment and other property and equipment during the three-month period of 2024 compared to the three-month period of 2023. Purchases of medical equipment were lower during 2024 compared to 2023 because a higher portion of the revenue growth in 2024 came from biomedical services that do not require capital equipment purchases.

Financing Cash Flow. Net cash provided by financing activities for the three-month period of 2024 was $0.6 million compared to $3.3 million for the three-month period of 2023. The amount of cash flow provided by financing activities during 2024 included net revolving line of credit borrowings under the 2021 Credit Agreement totaling $0.8 million and cash proceeds from employee stock option exercises and employee stock purchase plan proceeds totaling $0.2 million combined. These cash sources were partially offset by cash used to satisfy statutory withholding on employee stock based compensation plans totaling $0.4 million. Cash provided by financing activities during 2023 primarily related to net revolving line of credit borrowings under the 2021 Credit Agreement totaling $3.2 million and $0.6 million in cash proceeds from employee stock option exercises and employee stock purchase plan proceeds combined. These were partially offset by cash used to satisfy statutory withholding on employee stock based compensation plans totaling $0.3 million and $0.2 million to buy back the Company's common stock.

The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the unaudited condensed consolidated financial statements and the judgments and assumptions used are consistent with those described in the notes to the audited consolidated financial statements in our annual report on Form 10-K for the year ended December 31, 2023 filed with the SEC on April 10, 2024. There have been no material changes to our critical accounting policies described in the notes to the audited consolidated financial statements in our annual report on Form 10-K for the year ended December 31, 2023.

We are exposed to market risk from changes in foreign currency exchange rates and short-term interest rates. Market risks for changes in interest rates relate primarily to our debt obligations under our 2021 Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in our functional currency, which is the U.S. Dollar (“USD”) and include exposures primarily to the Canadian Dollar.

The Company periodically enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. We did not have any foreign currency derivative contracts outstanding at any time during the three months ended March 31, 2024. The maximum length of time over which we hedge our exposure to short-term interest rate risk is equal to the remaining term for the debt obligation being hedged. We had interest rate derivative contracts with a notional value of $20.0 million as of both March 31, 2024 and December 31, 2023.

We do not enter into derivative financial instruments for speculative or trading purposes. Our hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts, which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to accumulated other comprehensive income in the condensed consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in accumulated other comprehensive income is recorded in earnings in the condensed consolidated statements of operations and comprehensive loss on the same line as the gain or loss on the hedged item attributable to the hedged risk. We record the ineffective portion of interest rate hedging instruments, if any, to interest expense in the condensed consolidated statements of income. See Note 8 to our condensed consolidated financial statements for information related to the fair values of derivative instruments in our condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023, respectively, and information related to the effect of derivative instruments included in our condensed consolidated statements of operations and comprehensive loss including the amount of unrealized gain associated with our interest rate derivatives reported in accumulated other comprehensive income that was reclassified into earnings during the three months ended March 31, 2024 and 2023, respectively.

The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounting such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term.

In July 2017, the Financial Conduct Authority (the authority that regulates the London Interbank Offered Rate (“LIBOR”) announced its intent to stop compelling banks to submit rates for the calculation of LIBOR after 2021, and the administrator of LIBOR announced its intention to cease the publication of the one week and two month USD LIBOR settings immediately following December 31, 2021, and the remaining USD LIBOR settings immediately following the LIBOR publication on June 30, 2023. The one week and two month USD LIBOR settings were last published on December 31, 2021. Additionally, it is expected that banks no longer issue LIBOR-based debt after December 31, 2021. Accordingly, there is considerable uncertainty regarding the publication of such rates beyond these dates. The Alternative Reference Rates Committee (“ARRC”) has proposed that the Secured Overnight Financing Rate (“SOFR”) is the rate that represents best practice as the alternative to USD LIBOR for use in derivatives and other financial contracts that are currently indexed to USD LIBOR. ARRC has proposed a paced market transition plan to SOFR from USD LIBOR and organizations are currently working on industry-wide and company-specific transition plans as it relates to derivatives and cash markets exposed to USD LIBOR. On April 26, 2023, the Company amended its 2021 Credit Agreement with the First Amendment, discussed in Note 7 to the condensed consolidated financial statements, to provide for the replacement of LIBOR with Term SOFR as a benchmark interest rate. Prior to the First Amendment, net revolving loans under the 2021 Credit Agreement were indexed to USD LIBOR. As discussed in Note 8 to the condensed consolidated financial statements, on May 11, 2023, the Company settled its two outstanding interest rate swap agreements, which were indexed to USD LIBOR, and entered into a new interest rate swap agreement indexed to SOFR to coincide with the index change in the 2021 Credit Agreement, as amended. The new swap agreement has a notional value of $20 million, which is equal to the combined notional value of the two settled swap agreements. The term of the new swap agreement, which matches the April 26, 2028 expiration date of the 2021 Credit Agreement, as amended, extends past the term of the settled swap agreements by approximately 26 months. Because of the hedging relationships, a change of 50% in the market rate of SOFR would not have a material impact on our financial results.

We maintain a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that material information is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosures. Our CEO and CFO have evaluated these disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q and have determined that such disclosure controls and procedures were not effective due to a material weakness in internal control over financial reporting that was disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

As previously described in Part II, Item 9A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, we are implementing measures designed to ensure that the control deficiency contributing to the previously disclosed material weakness is remediated, such that the control is designed, implemented, and operating effectively. The Company is in the process of designing and implementing controls that will improve the Company's ongoing application of US GAAP related to revenue recognition for the Company's rental revenue contracts under ASC Topic 842, Leases and ASC Topic 606, Revenue from Contracts with Customers. These remediation actions remain in process in addition to further modifications deemed necessary to address the material weakness. We expect these changes to materially improve our internal controls.

The weakness will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. Management believes the remediation of this material weakness will be completed prior to the end of fiscal year 2024. However, there is no assurance as to when such remediation will be completed.

The Company has been implementing measures to remediate the material weakness in our internal control over financial reporting. Other than the remediation efforts underway, there were no changes in the Company's internal control over financial reporting during the three-month period ended March 31, 2024, which were identified in connection with management's evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

From time to time in the ordinary course of our business, we may be involved in legal and regulatory proceedings, the outcomes of which may not be determinable. The results of litigation and regulatory proceedings are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. We have insurance policies covering potential losses where such coverage is cost effective.

We are not at this time involved in any proceedings that we believe could have a material effect on our business, financial condition, results of operations or cash flows.

For information regarding factors that could affect our results of operations, financial condition and liquidity, refer to the section entitled “Risk Factors” in Part I, Item 1A in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on April 10, 2024.

A summary of our purchases of our common stock during the three months ended March 31, 2024 is as follows: